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OBJECTIVES The goal of this study was to determine the impact of race on identification of hypertrophic
cardiomyopathy (HCM).
BACKGROUND Sudden death in young competitive athletes is due to a variety of cardiovascular diseases (CVDs)
and, most commonly, HCM. These catastrophes have become an important issue for African
Americans, although HCM has been previously regarded as rare in this segment of the U.S.
population.
METHODS We studied the relationship of race to the prevalence of CVDs causing sudden death in our
national athlete registry, and compared these findings with a representative multicenter
hospital-based cohort of patients with HCM.
RESULTS Of 584 athlete deaths, 286 were documented to be due to CVD at ages 17  3 years; 156
(55%) were white, and 120 (42%) were African American. Most were male (90%), and 67%
participated in basketball and football. Among the 286 cardiovascular deaths, most were due
to HCM (n  102; 36%) or anomalous coronary artery of wrong sinus origin (n  37; 13%).
Of the athletes who died of HCM, 42 (41%) were white, but 56 (55%) were African
American. In contrast, of 1,986 clinically identified HCM patients, only 158 (8%) were
African American (p  0.001).
CONCLUSIONS In this autopsy series, HCM represented a common cause of sudden death in young and
previously undiagnosed African American male athletes, in sharp contrast with the infrequent
clinical identification of HCM in a hospital-based population (i.e., by seven-fold). This
discrepancy suggests that many HCM cases go unrecognized in the African American commu-
nity, underscoring the need for enhanced clinical recognition of HCM to create the opportunity
for preventive measures to be employed in high-risk patients with this complex disease. (J Am
Coll Cardiol 2003;41:974–80) © 2003 by the American College of Cardiology Foundation
Sudden death in the young athlete is always an unexpected
and tragic event with great impact on families, the commu-
nity, and medical establishment (1–7). Previously, we and
others have documented that the cause of such athletic field
deaths is predominantly structural cardiovascular disease
(CVD) (1,3–6). However, the demographic profile of these
devastating events is incompletely resolved, including the
impact of race. Premature sudden cardiovascular deaths,
including those in competitive athletes, has become a major
issue for African Americans, and identification of the causes
of these catastrophes is a priority (2,8,9). In the present
report, we utilized our unique registry (5) to analyze the
causes of sudden cardiac death in competitive athletes with
respect to race, and assess the relevance of these findings to
preventive and community medicine.
METHODS
Selection of subjects. The Minneapolis Heart Institute
Foundation registry was established in 1992 to systemati-
cally assemble, prospectively and retrospectively (from
1985), cases of young athletes who died suddenly. These
cases were primarily identified from news media accounts,
but also from a variety of other sources including informal
communications and reports from high schools and colleges
(5). A total of 584 young athletes who died suddenly were
consecutively enrolled in the registry to April 2000. Subjects
were initially considered for inclusion if they were: 1) truly
a competitive athlete, that is, a participant in an organized
team or individual sport requiring regular training and
competition while placing a high premium on excellence
and achievement (10), and 2) 35 years old while actively
engaged in competitive sports. The number of cases re-
ported to the registry have increased with time: 117 (20%)
before 1990; 105 (18%) from 1990 to 1994; and 362 (62%)
from 1995 to 1999. The largest number of reported cases in
a single year occurred in 1996 (n  70). Forty-two states
were represented, most commonly: California (n  31
cases), Florida (n  17 cases), Michigan and New York
(n  16 each cases), Ohio (n  15 cases), and Texas (n 
13 cases).
Of these 584 subjects, 298 were ultimately excluded from
the present study based on: 1) identification of primary
noncardiovascular causes of death (e.g., drug abuse, com-
plications of asthma, heat stroke, drowning, head trauma, or
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ruptured cerebral artery); 2) sudden death due to a blunt
chest blow in the absence of structural cardiac disease
(commotio cordis) (7); 3) incomplete postmortem or toxi-
cology examination, or one insufficient to establish the
probable cause of death based on the available clinical and
autopsy data; and 4) inability to track and obtain the
necessary diagnostic data due to confidentiality consider-
ations restricting access to autopsy information. The re-
maining 286 athletes constitute the principal study group.
Selected data from 134 athletes are included in a prior
report (5).
Data assembly. Upon initial identification, a systematic
tracking process was established to assemble information on
each case, including the autopsy report (with complete gross
anatomic, histologic, and toxicologic data), as well as per-
tinent clinical information. In selected instances, primary
pathologic materials were requested and analyzed, and,
when necessary, the findings were verified by direct com-
munication with medical examiners. Clinical information
(e.g., circumstances of collapse and preparticipation screen-
ing) was derived from written accounts and from telephone
interviews with family members, witnesses, or coaches. The
final diagnoses were based almost solely on the autopsy
findings in the vast majority of athletes. However, 46 (16%)
had cardiovascular evaluations during life, and, when appro-
priate, those data were considered in formulating the diag-
nosis and cause of death.
Diagnosis of hypertrophic cardiomyopathy (HCM). Our
primary diagnostic criterion for probable or definite evi-
dence of HCM was a hypertrophied nondilated left ventri-
cle (LV) in the absence of another cardiac or systemic
disease capable of producing the degree of hypertrophy
present (11–13). Required criteria were, as previously de-
scribed (5), heart weight of 500 g and 1 supporting
clinical or morphologic feature in any of the following
categories: 1) family history of HCM with or without
premature sudden death; 2) asymmetric pattern of LV
hypertrophy such as prominent bulging of the ventricular
septum into the outflow tract, or marked wall thickening
(ventricular septum 20 mm), and/or enlarged left atrium
with small ventricular chambers, fibrous outflow tract con-
tact plaque (on the septum), or markedly elongated mitral
valve leaflets; 3) histologic abnormalities of LV, including
marked disorganization of cardiac muscle cells (14), abnor-
mal intramural coronary arteries (15,16), and/or replace-
ment scarring (15,16). Alternatively, hearts with weight
500 g but with maximal LV wall thickness 20 mm were
also regarded as diagnostic of HCM.
Hearts that showed a modest, but otherwise unexplained,
increase in cardiac mass (heart weight 400 g in males and
350 g in females but 500 g) and mild LV wall
thickening (15 to 19 mm), but with one or no other
supporting diagnostic feature of HCM, were judged as
suggestive of HCM, although insufficient to warrant a
definitive diagnosis (5).
Clinical HCM cohort. For comparative purposes, a mul-
ticenter population of 1,986 patients with HCM who were
diagnosed clinically (12) was assembled from the outpatient
records of the University of Florida Health Sciences Cen-
ter (Gainesville) (n  75), St. Luke’s-Roosevelt Hospital
Center (New York) (n  107), Cleveland Clinic Founda-
tion (n  1,314), and Minneapolis Heart Institute (n 
490) specifically to ascertain the distribution of HCM
patients with respect to race. Data from these four centers
included all HCM patients referred to that institution, both
locally and from other regions.
These institutions were selected because of their recog-
nition as HCM centers, as well as location in large metro-
politan areas and/or regions generally accessible to large
numbers of African American patients. Therefore, the
cohort included a prominent component of largely un-
selected patients, as well as patients who were part of tertiary
center referral patterns.
Ages at initial institutional evaluation were 56 19 years;
1,060 of 1,986 (53%) were male. Maximal LV wall thick-
nesses obtained with two-dimensional echocardiography
were 20  5 mm (range, to 55 mm). Outflow obstruction
under basal conditions (Doppler-estimated gradient 30
mm Hg) was present in 693 of 1,986 (35%).
Statistical methods. Data are expressed as mean  SD.
Proportions were compared with the chi-square test, where
appropriate.
RESULTS
Demographic profile of athletes. In the 286 athletes who
died of CVD, ages were 9 to 40 years (mean, 17  3); 256
(90%) were male. Distribution according to race was: white
(n  156; 55%); African American (blacks of African
descent) (n  120; 42%); and other races (n  10; 3%),
including Asian (n  5; 2%); Hispanic (n  4; 1%); and
Native American (n  1; 0.3%). Most athletes were
competing in organized high school (n  188; 66%) or
college sports (n  53; 19%), and 12 (4%) were professional
athletes. The remaining 33 athletes (12%) were 14 years
and engaged in organized youth or junior high school
sports. Nineteen athletes (7%) were regarded as elite, having
achieved national or international levels of competition.
A variety of 18 competitive sports were represented, most
commonly basketball and football (combined: 192, 67%);
only in basketball were African American athletes more
common than whites (i.e., 63:35). Of the 286 athletes who
died suddenly of heart disease, 204 (71%) collapsed during
Abbreviations and Acronyms
ARVC  arrhythmogenic right ventricular
cardiomyopathy
CVD  cardiovascular disease
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
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or immediately after a training session (n 129) or a formal
athletic contest (n  75). The remaining 82 athletes (29%)
died either during mild recreational physical activities (n 
46), or while sedentary (n  36; including 11 during sleep).
Only 55 athletes (19%) were known to have experienced
symptoms that could have been cardiovascular in origin
(e.g., chest pain, exertional dyspnea, syncope, or recurring
dizziness).
Of the 286 athletes, information regarding preparticipa-
tion medical evaluations were available in 252. Customary
personal and family history and physical examination, or
other clinical evaluations, were performed as part of medical
clearance for high school or college sports in 247 of the 252
athletes (98%). Preparticipation examinations were docu-
mented in 98.6% of whites and 97.3% of African Americans
(p  NS).
Cardiovascular causes of sudden death in athletes. A
variety of CVDs were identified as the cause of sudden
death in the 286 athletes (Table 1). In three of these,
standard autopsy examination did not identify a cause of
death, but a clinical evaluation had previously documented
or strongly suggested long QT syndrome (17). Three other
athletes with Marfan’s syndrome did not have autopsies, but
the clinical circumstances of their death was judged most
consistent with aortic dissection and rupture (18).
Hypertrophic cardiomyopathy was the most common
cause of death and occurred in 102 athletes (36%). Maxi-
mum LV wall thickness was 23 5 mm, ranging to 40 mm,
and 30 mm in 12 athletes (11–13,19). Of the 102 athletes
with HCM, 9 had associated abnormalities that may have
contributed to death, including tunneled (bridged) left
anterior descending coronary artery (n  7) (20) and
coronary artery hypoplasia (n  2) (21).
The second most frequent cardiovascular cause of sudden
death was coronary artery anomalies of wrong sinus origin
(22,23) that were present in 37 athletes (13%); these were
left main coronary artery originating from the right (ante-
rior) sinus of Valsalva (n  32) and right coronary artery
from the left sinus of Valsalva (n  5) (Table 1). The
remaining 118 athletes died suddenly of a variety of cardiac
diseases or malformations, each of which comprised7% of
the overall study group. These included most commonly,
myocarditis (n  20), ruptured dissecting ascending aortic
aneurysm with or without evidence of Marfan’s syndrome (n
 12), and arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) (n  11) (Table 1) (24).
Relation of race to HCM and other CVDs. ATHLETES
WITH SUDDEN DEATH. Of the 102 competitive athletes
who died suddenly of HCM, most (56; 55%) were African
American and 42 (41%) were white (p  0.002); the
remaining 4 (4%) were of other races (Table 1, Fig. 1).
African American and white athletes with HCM did not
differ significantly with respect to age (17.1  2 years vs.
16.7  2 years), gender (98% vs. 95% male), maximum LV
wall thickness (23.0  5 mm vs. 22.2  5 mm), nor
competitive sport at the time of death (most commonly
basketball; 57% vs. 33%; p  NS). Arrhythmogenic right
ventricular cardiomyopathy and aortic valve stenosis were
both significantly more common in white than African
American athletes (Table 1, Fig. 2). Of 102 athletes who
died of HCM, the correct diagnosis was ultimately made
during life in only 3 (3%), of whom 2 were white and 1 was
African American.
Table 1. Frequency and Racial Differences for Cardiovascular Causes of Sudden Death in 286 Young Competitive Athletes
Cause of Death
No. (%)









HCM 102 (36) 99:3 17.0  2.5 42 (41) 56 (55) 4 (4) 0.002
Coronary artery anomalies of wrong sinus origin† 37 (13) 28:9 15.3  2.5 15 (40) 18 (49) 4 (11) NS
Indeterminant, possibly HCM‡ 29 (10) 27:2 17.9  4.0 15 (52) 12 (41) 2 (7) NS
Myocarditis 20 (7) 16:4 17.1  3.9 12 (60) 8 (40) 0 NS
Ruptured aortic aneurysm 12 (4) 9:3 18.4  5.1 8 (67) 4 (33) 0 NS
ARVC 11 (4) 9:2 17.0  2.4 10 (91) 1 (9) 0 0.033
Tunnelled coronary artery 11 (4) 11:0 16.4  3.0 8 (73) 3 (27) 0 NS
Aortic valve stenosis 10 (3) 10:0 15.4  1.5 10 (100) 0 0 0.017
Atherosclerotic coronary artery disease 10 (3) 9:1 17.5  3.9 7 (70) 3 (30) 0 NS
Idiopathic dilated cardiomyopathy 9 (3) 8:1 17.9  1.8 5 (56) 4 (44) 0 NS
Mitral valve prolapse 9 (3) 8:1 18.4  6.5 5 (56) 4 (44) 0 NS
Coronary artery hypoplasia 8 (2) 8:0 18.8  9.1 7 (88) 1 (12) 0 NS
Other congenital coronary anomalies§ 8 (2) 5:3 15.6  2.5 6 (80) 2 (20) 0 NS
Cardiac sarcoidosis 3 (1) 3:0 21.3  4.6 0 3 (100) 0 NS
Long QT syndrome 3 (1) 3:0 16.7  0.6 2 (67) 1 (33) 0 NS
Congenital heart disease 3 (1) 2:1 14.0  2.3 3 (100) 0 0 NS
Myocardial infarction (etiology unresolved) 1 (0.3) 1:0 15.0  0.0 1 (100) 0 0 NS
*Comparison of the proportion of athletes with each individual cardiovascular abnormality calculated relative to the total number of African American (n  120) or white athletes
(n  156) who died of heart disease; †includes 32 with anomalous left main coronary artery from right (anterior) sinus of Valsalva, and 5 with anomalous right coronary artery
from left sinus; ‡hearts with autopsy findings regarded as consistent with HCM, but insufficient to be diagnostic of the disease; §includes origin of left anterior descending
coronary artery from pulmonary trunk (n 1), intussusception associated with hypoplastic left circumflex coronary artery (n 1), single coronary artery (n 2), acute angulation
of left coronary artery (n 3), and coronary artery aneurysm (n 1); includes secundum atrial septal defect (n 1), coarctation of aorta (n 1), and double outlet right ventricle
(n  1).
A-A  African American; ARVC  arrhythmogenic right ventricular cardiomyopathy; F  female; HCM  hypertrophic cardiomyopathy; M  male.
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CLINICALLY IDENTIFIED HCM PATIENTS. In the assembled
multicenter, hospital-based cohort of 1,986 HCM patients,
1,784 (90%) were white and only 158 (8%) were African
American (Fig. 1); the remaining 44 (2%) were of other
races. The prevalence of African American patients with
HCM was highest at the University of Florida Health
Sciences Center (11 of 75; 15%), lowest at the Minneapolis
Heart Institute (10 of 490; 2%), and intermediate at the
Cleveland Clinic (130 of 1,314; 10%) and St. Luke’s-
Roosevelt Hospital (7 of 107; 6%).
Therefore, the prevalence of African Americans among
athletes who died suddenly of HCM (56 of 102; 55%) was
significantly greater than the representation of African
Americans in the cohort of HCM patients clinically diag-
nosed within outpatient and inpatient hospital settings (158
of 1,986; 8%; p  0.001). Also, clinically identified African
American patients with HCM were older (59.5  16 years)
and more commonly women (64%), and less frequently had
outflow obstruction (25%), compared with the HCM pa-
tients of other races (54.0  19 years, 45% and 36%,
respectively; p 0.001, 0.001, and 0.01. African Americans
and those of other races with HCM did not differ with
respect to maximum LV wall thickness (20.5  5 mm vs.
20.8  6 mm, respectively).
Figure 1. Distribution according to race shown separately for the overall autopsy-based study population of 286 trained competitive athletes who died
suddenly from a variety of cardiovascular diseases (left), for those 102 athletes studied at autopsy who died of hypertrophic cardiomyopathy (HCM) (center),
and a clinically identified, multicenter hospital-based cohort of 1,986 patients with HCM (right). SCD  sudden cardiac death.
Figure 2. Impact of race on cardiovascular causes of sudden death in the population of 286 competitive athletes, with data shown for those seven structural
heart diseases represented by at least 10 deaths. Ao  aortic; ARVC  arrhythmogenic right ventricular cardiomyopathy; CAD  atherosclerotic coronary
artery disease; HCM  hypertrophic cardiomyopathy.
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DISCUSSION
Demographics and causes of athletic field deaths.
Sudden death on the athletic field in young participants has
been of considerable interest in the lay and medical com-
munities (1–7,10,25). Indeed, in studies from the U.S.
(including the present one), a variety of predominantly
congenital CVDs have been documented to be responsible
for most of these deaths, with HCM the most common
condition occurring in about one-third of cases (1,3–5,25).
Our large prospective registry of sudden deaths in young
athletes proved instructive with regard to the epidemiology
of these catastrophic events and particularly the significance
of race in HCM. We found that the majority of athletes
who died of HCM were African Americans (i.e., 55%).
While characterization of the racial composition of the
entire athlete population in the U.S. is well beyond the
scope of the present study, this predominance of African
Americans with HCM cannot be solely attributable to
relative rates of sports participation among the races. In-
deed, there are about 8 million high school and college
athletes (of both genders) in the U.S. each year, and the
overall U.S. population includes 2.7 million male and 2.7
million female African Americans between the ages of 15
and 24 years. Therefore, for African Americans to comprise
55% of high school and college athletes, fully 80% of all
African Americans in the U.S. age 15 to 24 years would
have to be members of organized athletic programs. Obvi-
ously, because this cannot be the case, it is most reasonable
to assume that participants in organized sports nationally
are not predominantly black, and that African Americans
probably have a representation in the overall athlete popu-
lation similar to that in the general U.S. population (i.e.,
about 15%) (26).
HCM in African Americans. Historically, HCM has been
regarded as a condition that uncommonly affects and rarely
is diagnosed in black patients. The published medical
literature reflects this view in that HCM patients reported
by race are very uncommonly identified as black (27). This
may be explained, in part, by the fact that the tertiary center
referral institutions that have traditionally assessed the
largest numbers of HCM patients (in the U.S., Canada, and
Europe), and contributed substantially to the literature, have
generally evaluated relatively few black patients with CVD
(12,28,29).
Indeed, the observation that clinically diagnosed HCM
patients are uncommonly African American is supported by
the large multicenter HCM population assembled for the
present analysis in which only 8% of about 2,000 patients
with this disease were reported as African American (range,
2% to 15% for each of the four institutions). Therefore,
HCM was seven times more common in African Americans
when the disease was identified for the first time at autopsy
after a sudden death on the athletic field than when
recognized within a clinically diagnosed patient cohort. This
suggests that many HCM cases in African Americans go
undetected in the community. Furthermore, African Amer-
icans appear to comprise a smaller proportion of our
multicenter clinical HCM population (i.e., 8%) than would
be expected from their representation in the general U.S.
population (i.e., 16%) (26).
This finding of a large disparity in the clinical identifi-
cation of HCM between African Americans and whites is
provocative and can possibly be explained in a number of
ways. First, in general terms, there is a disproportionate
access to subspecialty medical care between the black and
white communities, specifically with regard to referral for
specialized cardiovascular procedures (30–36). This percep-
tion suggests that underdiagnoses of HCM in young Afri-
can Americans may be attributable, in large measure, to
socioeconomic factors that potentially limit access to med-
ical specialty referral (and echocardiography), which is
usually a prerequisite for the clinical diagnosis of HCM.
Consequently, it may be much less likely for young black
males (compared with their white counterparts) to be
identified with HCM, particularly if asymptomatic. Of
note, our clinically identified African American patients
with HCM were not predominantly male (as is consistently
the case in white patients with this disease) (12,13,19,28),
but, rather unexpectedly, were more commonly female (i.e.,
64%). Finally, the well-recognized difficulties in diagnosing
HCM in generally healthy asymptomatic populations (1,25)
are likely to be accentuated in African Americans for whom
HCM-related LV hypertrophy may be ascribed erroneously
to mild degrees of systemic hypertension (37).
Preparticipation screening. Our findings may also be
relevant to the issues surrounding preparticipation screening
for competitive athletes in the U.S. (25). We found no
obvious differences in the frequency with which standard
screening and cardiovascular evaluations were carried out
between African American and white athlete populations.
The failure to identify during life a substantial number of
athletes (either black or white) who died suddenly with
HCM raises the question of the efficacy attributable to
customary screening as it is generally practiced in the U.S.
with only a history and physical examination (38,39).
Certainly, the rigor of preparticipation screening has been of
concern for both high school (38) and college-age (39)
competitive athlete populations, as well as the implicit
limitations of the history and physical examination in
identifying or raising the suspicion of HCM (and other
CVDs). Of note, in Italy, preparticipation screening em-
ploys an obligatory 12-lead electrocardiogram (40), which
has been shown to increase the likelihood that HCM will be
diagnosed before competitive athletics are undertaken (41).
Significance of the findings. Alternatively, it is possible
that HCM in African Americans may represent a more
virulent form of the disease, possibly due to a malignant
genetic substrate when associated with exercise (42,43), and,
thereby, predisposing to sudden death on the athletic field
in susceptible individuals. However, regardless of these
considerations, it is our aspiration that the present report
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will trigger greater awareness that HCM not uncommonly
occurs and is an important cause of sudden death in young
African American males, thereby creating a higher index of
suspicion and ultimately more frequent clinical HCM
diagnoses in such athletes. Indeed, the failure to identify
HCM in young African American athletes has important
and potentially life-threatening consequences. Specifically,
there is the possibility that such individuals will not be
afforded important options, that is, disqualification from in-
tense competitive sports (in accord with recommendations of
Bethesda Conference #26) (10,44) to reduce sudden death risk
during physical activity, nor employment of potentially life-
saving prophylactic interventions such as the implantable
cardioverter-defibrillator in high-risk HCM patients (45).
Study limitations. The present study is a retrospective
autopsy-based analysis, comprised largely of athletes with-
out cardiovascular evaluation or diagnosis during life, for
whom we had no access to family screening or laboratory-
based genetic analysis (12,42,43). These patient selection
factors make any comparisons of clinical expression and
outcome, between our autopsy series of competitive athletes
and the hospital-based patient cohort, exceedingly difficult.
Therefore, in this study, our multicenter cohort of clinically
identified HCM patients was reserved solely for compari-
sons of prevalence.
The assembly of this large series of athletic field deaths
required substantial reliance on news media accounts for the
identification of cases. We recognize that this process could
have created certain selection biases relevant to our autopsy-
based series. For example, the sudden deaths of non-elite
athletes are probably less likely to achieve media visibility,
thereby underestimating the frequency with which sudden
deaths occur. Due to these selection factors, as well as the
absence of a systematic national reporting registry for such
deaths, precise estimates of the prevalence of athletic field
catastrophes in young athletes of all races are beyond the
scope of the present study.
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